These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 25137254)

  • 21. N-Alkylpyrido[1',2':1,5]pyrazolo-[4,3-d]pyrimidin-4-amines: A new series of negative allosteric modulators of mGlu1/5 with CNS exposure in rodents.
    Felts AS; Rodriguez AL; Morrison RD; Venable DF; Blobaum AL; Byers FW; Daniels JS; Niswender CM; Jones CK; Conn PJ; Lindsley CW; Emmitte KA
    Bioorg Med Chem Lett; 2016 Apr; 26(8):1894-900. PubMed ID: 26988308
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacological and molecular characterization of the positive allosteric modulators of metabotropic glutamate receptor 2.
    Lundström L; Bissantz C; Beck J; Dellenbach M; Woltering TJ; Wichmann J; Gatti S
    Neuropharmacology; 2016 Dec; 111():253-265. PubMed ID: 27590915
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structural determinants of allosteric antagonism at metabotropic glutamate receptor 2: mechanistic studies with new potent negative allosteric modulators.
    Lundström L; Bissantz C; Beck J; Wettstein JG; Woltering TJ; Wichmann J; Gatti S
    Br J Pharmacol; 2011 Sep; 164(2b):521-37. PubMed ID: 21470207
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Functional impact of allosteric agonist activity of selective positive allosteric modulators of metabotropic glutamate receptor subtype 5 in regulating central nervous system function.
    Noetzel MJ; Rook JM; Vinson PN; Cho HP; Days E; Zhou Y; Rodriguez AL; Lavreysen H; Stauffer SR; Niswender CM; Xiang Z; Daniels JS; Jones CK; Lindsley CW; Weaver CD; Conn PJ
    Mol Pharmacol; 2012 Feb; 81(2):120-33. PubMed ID: 22021324
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Group I and group II metabotropic glutamate receptor allosteric modulators as novel potential antipsychotics.
    Walker AG; Conn PJ
    Curr Opin Pharmacol; 2015 Feb; 20():40-5. PubMed ID: 25462291
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Positive Allosteric Modulators of Metabotropic Glutamate Receptor 5 as Tool Compounds to Study Signaling Bias.
    Arsova A; Møller TC; Hellyer SD; Vedel L; Foster SR; Hansen JL; Bräuner-Osborne H; Gregory KJ
    Mol Pharmacol; 2021 May; 99(5):328-341. PubMed ID: 33602724
    [TBL] [Abstract][Full Text] [Related]  

  • 27. mGlu1 receptor as a drug target for treatment of substance use disorders: time to gather stones together?
    Dravolina OA; Zvartau E; Danysz W; Bespalov AY
    Psychopharmacology (Berl); 2017 May; 234(9-10):1333-1345. PubMed ID: 28285325
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Allosteric modulators enhance agonist efficacy by increasing the residence time of a GPCR in the active state.
    Cao AM; Quast RB; Fatemi F; Rondard P; Pin JP; Margeat E
    Nat Commun; 2021 Sep; 12(1):5426. PubMed ID: 34521824
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biotransformation of a novel positive allosteric modulator of metabotropic glutamate receptor subtype 5 contributes to seizure-like adverse events in rats involving a receptor agonism-dependent mechanism.
    Bridges TM; Rook JM; Noetzel MJ; Morrison RD; Zhou Y; Gogliotti RD; Vinson PN; Xiang Z; Jones CK; Niswender CM; Lindsley CW; Stauffer SR; Conn PJ; Daniels JS
    Drug Metab Dispos; 2013 Sep; 41(9):1703-14. PubMed ID: 23821185
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Positive allosteric modulators of metabotropic glutamate 1 receptor: characterization, mechanism of action, and binding site.
    Knoflach F; Mutel V; Jolidon S; Kew JN; Malherbe P; Vieira E; Wichmann J; Kemp JA
    Proc Natl Acad Sci U S A; 2001 Nov; 98(23):13402-7. PubMed ID: 11606768
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design and synthesis of systemically active metabotropic glutamate subtype-2 and -3 (mGlu2/3) receptor positive allosteric modulators (PAMs): pharmacological characterization and assessment in a rat model of cocaine dependence.
    Dhanya RP; Sheffler DJ; Dahl R; Davis M; Lee PS; Yang L; Nickols HH; Cho HP; Smith LH; D'Souza MS; Conn PJ; Der-Avakian A; Markou A; Cosford ND
    J Med Chem; 2014 May; 57(10):4154-72. PubMed ID: 24735492
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacological enhancement of mGlu1 metabotropic glutamate receptors causes a prolonged symptomatic benefit in a mouse model of spinocerebellar ataxia type 1.
    Notartomaso S; Zappulla C; Biagioni F; Cannella M; Bucci D; Mascio G; Scarselli P; Fazio F; Weisz F; Lionetto L; Simmaco M; Gradini R; Battaglia G; Signore M; Puliti A; Nicoletti F
    Mol Brain; 2013 Nov; 6():48. PubMed ID: 24252411
    [TBL] [Abstract][Full Text] [Related]  

  • 33. GluD1, linked to schizophrenia, controls the burst firing of dopamine neurons.
    Benamer N; Marti F; Lujan R; Hepp R; Aubier TG; Dupin AAM; Frébourg G; Pons S; Maskos U; Faure P; Hay YA; Lambolez B; Tricoire L
    Mol Psychiatry; 2018 Mar; 23(3):691-700. PubMed ID: 28696429
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent patents on positive allosteric modulators of the metabotropic glutamate 5 receptor as a potential treatment for schizophrenia.
    Kanuma K; Aoki T; Shimazaki Y
    Recent Pat CNS Drug Discov; 2010 Jan; 5(1):23-34. PubMed ID: 19832691
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An Integrated Approach for Screening and Identification of Positive Allosteric Modulators of N-Methyl-D-Aspartate Receptors.
    Jambrina E; Cerne R; Smith E; Scampavia L; Cuadrado M; Findlay J; Krambis MJ; Wakulchik M; Chase P; Brunavs M; Burris KD; Gallagher P; Spicer TP; Ursu D
    J Biomol Screen; 2016 Jun; 21(5):468-79. PubMed ID: 26838761
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Atypical signaling of metabotropic glutamate receptor 1 in human melanoma cells.
    Gelb T; Pshenichkin S; Hathaway HA; Grajkowska E; Dalley CB; Wolfe BB; Wroblewski JT
    Biochem Pharmacol; 2015 Nov; 98(1):182-9. PubMed ID: 26291396
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy switching SAR of mGluR5 allosteric modulators: highly potent positive and negative modulators from one chemotype.
    Sams AG; Mikkelsen GK; Brodbeck RM; Pu X; Ritzén A
    Bioorg Med Chem Lett; 2011 Jun; 21(11):3407-10. PubMed ID: 21531137
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Kinetic and system bias as drivers of metabotropic glutamate receptor 5 allosteric modulator pharmacology.
    Sengmany K; Hellyer SD; Albold S; Wang T; Conn PJ; May LT; Christopoulos A; Leach K; Gregory KJ
    Neuropharmacology; 2019 May; 149():83-96. PubMed ID: 30763654
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exploration of allosteric agonism structure-activity relationships within an acetylene series of metabotropic glutamate receptor 5 (mGlu5) positive allosteric modulators (PAMs): discovery of 5-((3-fluorophenyl)ethynyl)-N-(3-methyloxetan-3-yl)picolinamide (ML254).
    Turlington M; Noetzel MJ; Chun A; Zhou Y; Gogliotti RD; Nguyen ED; Gregory KJ; Vinson PN; Rook JM; Gogi KK; Xiang Z; Bridges TM; Daniels JS; Jones C; Niswender CM; Meiler J; Conn PJ; Lindsley CW; Stauffer SR
    J Med Chem; 2013 Oct; 56(20):7976-96. PubMed ID: 24050755
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis and pharmacological evaluation of bivalent tethered ligands to target the mGlu
    Fulton MG; Loch MT; Rodriguez AL; Lin X; Javitch JA; Conn PJ; Niswender CM; Lindsley CW
    Bioorg Med Chem Lett; 2020 Jul; 30(13):127212. PubMed ID: 32371100
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.